Moderna, Inc. (MRNA)

Moderna's stock (MRNA) has experienced significant fluctuations in the past six months. The stock has seen a substantial increase over the last year. In the first quarter of 2026, Moderna's stock soared. However, in February 2026, the stock experienced a drop following a regulatory update regarding its seasonal flu vaccine candidate. Earlier, in November 2025, the stock fell to a 52-week low due to declining COVID-19 vaccine sales and concerns about the company's profitability and high research and development spending.

Demand for some of Moderna's key products, particularly its respiratory vaccines, exhibits seasonality. Respiratory vaccines are seasonal, and their demand can be inconsistent and subject to pricing pressure. Moderna is actively working to build a recurring, seasonal revenue stream from its flu and RSV vaccine candidates.

Moderna, Inc. is an American pharmaceutical and biotechnology company specializing in mRNA therapeutics and vaccines, operating within the Healthcare sector and Biotechnology industry. The company leverages its mRNA platform to develop medicines that instruct cells to produce proteins to fight or prevent diseases. Moderna's major products include the Moderna COVID-19 vaccine (Spikevax) and an RSV vaccine (Mresvia). The company has a diverse development pipeline comprising 45 therapeutic and vaccine programs, with 37 in clinical development, including vaccines for various viruses and treatments for rare diseases.

Moderna operates globally, with net sales distributed across the United States (55.1%), Europe (18.5%), and other regions (26.4%). The company has a commercial presence in 11 countries and distribution agreements to supply its COVID-19 vaccine in 45 countries. Its corporate headquarters is located in Cambridge, Massachusetts, U.S., with additional offices in various countries.

Moderna's brand reputation in the past year has been shaped by its scientific achievements and legal challenges. The company solidified its position in mRNA-based medicine through its pioneering vaccine development. However, Moderna has also faced scrutiny over executive stock sales and patent disputes. A significant event impacting its reputation in early 2026 was the settlement of a patent dispute with Arbutus Biopharma and Genevant Sciences GmbH, where Moderna agreed to pay up to $2.25 billion. Several insiders have sold shares in the past year.

Moderna, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 63% to 75.51% of the company's stock is held by institutional owners, including Vanguard Group Inc., BlackRock, Inc., Fmr Llc, Baillie Gifford & Co, and State Street Corp. Insiders own approximately 7.87% to 10.80% of Moderna's stock.